Abstract:
PROBLEM TO BE SOLVED: To provide new treatment compositions and methods for using the same in anti-angiogenesis and anti-tumor treatments. SOLUTION: The new compositions are each provided by containing an anti-VEGF antibody or its antigen-bonding fragment of a biologically effective amount, and the antibody bonds with an epitope which is essentially the same as a monoclonal antibody ATCC PTA 1595, and significantly inhibits the bonding of the VEGF with a VEGF receptor VEGFR2(KDR/Flk-1), without significantly inhibiting the bonding of the VEGF with a VEGF receptor VEGFR1(Flt-1). COPYRIGHT: (C)2011,JPO&INPIT
Abstract:
Methods comprising mixing at least one nano-porous particle into a homogeneous solution of a polymer and a diluent at an elevated temperature to form a mixture; and cooling the mixture to solidify the polymer. Membranes comprising at least one nano-porous particle; and a polymer; wherein the at least one nano-porous particle comprises pores ranging from about 0.1 nanometers to about 10,000 nanometers in size.
Abstract:
PROBLEM TO BE SOLVED: To provide various compositions and methods for use in overcoming restriction of precedent techniques and achieving specific blood coagulation by providing new compositions and methods used for achieving specific coagulation, e.g., coagulation in tumor blood circulatory system, and controlled in adverse effects. SOLUTION: Ligands containing the following (a) and (b) are provided: (a) a first joint domain binding with disease cells, components of disease-related blood circulatory system or components of disease-related stroma; (b) a coagulation factor to which the first joint domain is bound to be active or a second joint domain binding with the coagulation factor. COPYRIGHT: (C)2009,JPO&INPIT
Abstract:
PROBLEM TO BE SOLVED: To provide a new therapeutic use related to a bacteriocidal property/permeability-increasing (BPI) protein product, including the treatment of chronic cardiac diseases. SOLUTION: The present invention provides a method for administering a BPI protein product for treating chronic cardiac diseases (chronic ischemic cardiac failures, cardiac myopathy, congenital heart deficiency, and the like), a method for simultaneously administering the BPI protein product and the second treating agent selected from the group consisting of diuretics, vasodilatators and β-blockers, and the use of the BPI protein product for producing medicines for treating the diseases. COPYRIGHT: (C)2007,JPO&INPIT